VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide
Missionpharma could assist with low-cost manufacturing, clinical studies and distribution under the proposed collaboration.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VolitionRx (VNRX) signed a non-binding letter of intent with Missionpharma to explore developing and launching its prototype NETosis test worldwide.
The proposed collaboration concerns Volition's finger-prick lateral flow technology, designed for testing outside centralized laboratories. Volition reported that prototype results were highly correlated with its automated Nu.Q NETs test in critically ill sepsis patients. Its intended initial clinical focus is developing and validating a tool to assess urgency and predict outcomes in newborns and young infants with sepsis.
Volition hopes the collaboration will accelerate commercialization and access, particularly in resource-constrained countries and humanitarian emergency settings. The agreement establishes a basis for exploration, rather than a binding development or launch commitment.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointMissionpharma letter of intent establishes a basis to explore worldwide development and launch of Volition's prototype.
- Minor point. Forward-looking: it has not happened yet and may not happen.Initial clinical development is intended to focus on validating neonatal sepsis triage and outcome prediction.
- Minor point. Forward-looking: it has not happened yet and may not happen.Missionpharma's potential support includes low-cost manufacturing, clinical studies and distribution.
Negative
- Moderate pointNon-binding agreement leaves development and launch exploratory rather than committed.
Details
Market Reaction – VNRX
On Oct 27, the day this news came out, the latest delayed price for VNRX is 2.18% below the previous close. Argus tracked a trough of -9.7% from its starting point during tracking. Our momentum scanner has recorded 26 alerts for this stock so far that day. The latest delayed price is $0.17. Relative volume is exceptionally heavy at 24.9x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Historical Context
-
Advanced a finger-prick lateral-flow assay and cited pursuit of NGO and strategic partnerships.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
letter of intent financial
netosis medical
neutrophil extracellular traps medical
prognostication medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dr. Gaetan Michel, Chief Operating Officer, Volition, commented:
"We recently announced a major technical milestone: results utilizing our lateral flow prototype are highly correlated with results utilizing Volition's established automated Nu.Q® NETs test in critically ill sepsis patients1, thereby expanding beyond centralized laboratory testing. This finger prick sample test could be used worldwide, beyond solely high-income countries.
"The Nu.Q® NETs test quantifies circulating nucleosomes and Neutrophil Extracellular Traps (NETs) as early indicators of hyper-inflammation, and we believe its use will cover a broad range of diseases including sepsis and septic shock.
"By enabling decentralized testing, our total addressable market expands, and, with the help of Missionpharma, we hope to accelerate commercialization and market access, particularly in resource-constrained countries and humanitarian emergency settings."
Agustin Travaini, Director, Strategic Partnerships, UN, Missionpharma, commented:
"At Missionpharma, we are proud to have strong partnerships with a broad institutional base, including United Nations ("UN") agencies specialized in global health and humanitarian response.
"We aim to explore opportunities to closely work with Volition in the introduction, development, and scale-up of its LFT test for NETosis, potentially assisting with low-cost manufacturing, clinical studies, and distribution.
"We see a very strong interest from our partners and customers in Volition's innovative diagnostic solutions, particularly in low- and middle-income countries ("LMICs") and humanitarian emergency settings, and are excited to collaborate with the aim of saving millions of children's lives annually."
Dr Andrew Retter, Medical Consultant, Volition, said:
"The proprietary Nu.Q® technology, including Volition's finger-prick lateral flow prototype, has broad clinical utility.
"Following on from discussions with key global health institutions, it is clear that Volition's clinical intended use should initially focus on one well defined use: developing and validating a tool for triaging and prognostication for neonatal sepsis (sepsis in newborns and young infants).
"An estimated 2.3 million newborns die each year2. Sepsis is a major contributor in settings such as LMICs, especially in
"The Nu.Q® NETs LFT prototype test is a potential gamechanger. We are delighted that Volition and Missionpharma have now established a basis for collaboration with initial focus on evaluating the lateral flow prototype with a well-defined and impactful first clinical utility, sepsis in newborns and young infants.
"We look forward to continuing our work together with Missionpharma."
For partnership, licensing, or media inquiries, contact our alliance team directly at mediarelations@volition.com.
- Data on File, Volition
- The United Nations Inter-agency Group for Child Mortality Estimation. Levels and trends in child mortality: Report 2025 (accessed Sept 2026)
- Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions.
Geneva : World Health Organization; 2020 Report (accessed Sept 2026)
About Missionpharma
Missionpharma is a global leader in the sale and distribution of healthcare products and innovative solutions, supplying UN agencies, international and local non-governmental development organizations, and public and private sector institutions, including the WHO and Ministries of Health across LMICs.
Since 1975 Missionpharma has contributed to improving global health by supplying quality medicines, medical devices, and health kits to people all over the world, every year improving the lives of more than 100 million people.
Since 2012, Missionpharma has been a proud member of CFAO Healthcare, the healthcare division of CFAO Group, owned by Toyota Tsusho Corporation.
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries: Ellen Amonoo, Volition, mediarelations@volition.com
Safe Harbor Statement
Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nu.Q®, rNuq™, Nucleosomics™, Capture-PCR™ and Capture-Seq™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.
View original content:https://www.prnewswire.com/news-releases/volitionrx-signs-loi-with-missionpharma-to-explore-the-development-and-launch-of-volitions-lateral-flow-technology-for-netosis-worldwide-302920590.html
SOURCE VolitionRx Limited
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did VolitionRx and Missionpharma agree to explore?
VolitionRx and Missionpharma signed a non-binding letter of intent to explore developing and launching Volition's prototype lateral flow technology for NETosis worldwide. The intended initial clinical focus is evaluating a tool for assessing urgency and predicting outcomes in newborns and young infants with sepsis.
How could Missionpharma support VolitionRx's NETosis test development?
Missionpharma aims to explore support for low-cost manufacturing, clinical studies and distribution. Its proposed involvement covers introduction, development and scale-up of the test, with interest in low- and middle-income countries and humanitarian emergency settings.